Last reviewed · How we verify
NCT06166121
Study on Hyperlipidemia Combined With Carotid Atherosclerosis With ShenJu Granules
NA trial testing ShenJu in Hyperlipidemia in 80 participants. Status unknown.
30 October 2023
Quick facts
| Lead sponsor | Guangdong Provincial Hospital of Traditional Chinese Medicine |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 20 September 2023 |
| Primary completion | 30 October 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 2 locations across China |
Drugs / interventions tested
- ShenJu
- Placebo
Conditions studied
- Hyperlipidemia — all drugs for Hyperlipidemia →
- Carotid Atherosclerosis — all drugs for Carotid Atherosclerosis →
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Who can join
Adults 15 to 65, any sex, with Hyperlipidemia or Carotid Atherosclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study focuses on PWV as the main outcome, aiming to evaluate the efficacy and safety of ShenJu in treating patients with hyperlipidemia combined with carotid atherosclerosis, and provide a basis for traditional Chinese medicine treatment of hyperlipidemia combined with carotid atherosclerosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06166121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemia
Currently open trials in the same condition.
- NCT06966258 — Inspire HER: Inspiring the Heart and Emotions for Radical Health · NA · recruiting
- NCT07216482 — A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) · Phase 3 · recruiting
- NCT06615609 — "Smart Family Doctor" Assisted Comprehensive Management of Secondary Prevention Among Post Coronary Artery Bypass Graft · NA · recruiting
- NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
- NCT06603363 — Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT · NA · recruiting
Other Guangdong Provincial Hospital of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07352137 — Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast R · NA · enrolling by invitation
- NCT06908473 — Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients · Phase 3 · enrolling by invitation
- NCT06328153 — Efficacy and Mechanism of FSN Treatment for Senile Knee Osteoarthritis · NA · unknown
- NCT06001112 — Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis · NA · completed
- NCT06377761 — Study on Heart Failure with Preserved Ejection Fraction with Qishen Granules · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06166121 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial Hospital of Traditional Chinese Medicine
- Last refreshed: 12 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06166121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing